



Erythromycin Oral Tablets

The Issue: Erythromycin 250 mg oral tablets have been discontinued from the sole manufacturer in Canada. NH pharmacy has a small supply remaining, but will be transitioning to the only other oral solid erythromycin product available: erythromycin delayed release 333 mg capsules (ERYC®).

Clinical Use: Erythromycin is a macrolide antibiotic used for treatment and prophylaxis of infections caused by susceptible bacteria and off-label as a gastromotility agent.

Practice Implications:

- Staff and clinicians should be aware of this drug discontinuation and the alternative product soon-to-be available.
- The NH therapeutic interchange policy (TIP) for erythromycin delayed release 333 mg PO TID to erythromycin 250 mg PO QID will no longer be in place.
- Sites may see both products available as pharmacies use up remaining supply of the 250 mg tablets and start stocking the delayed release capsules.
- Pharmacists will provide order clarifications as required.

August 12, 2022 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage		For further information contact: Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation	✓	
	Product Change	✓	
	Best Practice		

*Alternatives are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.